On April 29, 2021 Vibliome Therapeutics, LLC, reported that it closed a $16mm Series A round of financing to advance its proprietary technology supporting the development of small molecule therapeutics targeting clinically-relevant signaling pathways (Press release, Vibliome, APR 29, 2019, View Source [SID1234580056]).
Deerfield Management was the sole investor in the Series A financing round and will be providing operational support. Vibliome has discovered a new systematic approach for the development of small molecule kinase inhibitors with unique profiles and a very high degree of selectivity. The company’s focus on medicinal chemistry gives it a distinct advantage in developing high quality inhibitors against exciting new targets. Vibliome’s technology also supports lead generation for improved inhibitors against validated and novel targets by taking advantage of new mechanisms of binding and dierentiated target combinations. This platform technology is ideally suited to support emerging therapeutic approaches for cancer and other diseases where selective enzyme targeting is needed.
There are over 500 kinases encoded by the human genome which control nearly all cellular functions by phosphorylating proteins. Aberrations in the control of cell metabolism, division, growth and death are hallmarks in the development of cancer, and kinase inhibitors have been shown to be eective in targeting genetic mutations and fusions that drive cancer progression. "The versatility of our chemistry platform oers many opportunities for variation while maintaining a common general architecture," said Robert Goodwin, Vibliome’s CEO. "We are very excited to leverage Deerfield’s support as we develop new therapeutic options for patients, particularly in oncology."